<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577094</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0429</org_study_id>
    <nct_id>NCT02577094</nct_id>
  </id_info>
  <brief_title>Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia</brief_title>
  <acronym>EPRALLO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab&#xD;
      radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2&#xD;
      before allogeneic stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Physical examination (screening and follow-up)&#xD;
&#xD;
        -  Complete blood counts (screening and follow-up)&#xD;
&#xD;
        -  Dosage of FLT3-ligand in plasma (screening and follow-up)&#xD;
&#xD;
        -  Blood ionogramme, creatinine hepatic work-up (screening and follow-up)&#xD;
&#xD;
        -  Left ventricular ejection fraction at pre-implant assessment&#xD;
&#xD;
        -  Immunization test (screening and follow-up)&#xD;
&#xD;
        -  Bone marrow aspiration or/and blood CD 22 immunophenotype for minimal residual disease&#xD;
           evaluation (screening and follow-up)&#xD;
&#xD;
        -  All exams which were initially abnormal and which are necessary for response evaluation&#xD;
           and All exams which are needed in case of relapse suspicion.&#xD;
&#xD;
        -  Pharmacokinetic of 90Y-hLL2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose (MTD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Patient toxicity will be evaluated according to NTCAE V4 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival at one year post-transplant</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse at 1 year post-transplant</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality at day 100 post-transplant</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality at one year post-transplant</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic reconstitutions post-transplant</measure>
    <time_frame>Month 3</time_frame>
    <description>Biological follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitutions post-transplant</measure>
    <time_frame>Month 3</time_frame>
    <description>Biological follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>Month 3 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism post-transplant</measure>
    <time_frame>Month 3</time_frame>
    <description>Blood sample and/or bone marrow analysis by molecular biology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual disease post-transplant</measure>
    <time_frame>Month 3 and Month 12</time_frame>
    <description>by flow cytometry analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of RIT</measure>
    <time_frame>Week 6 and Month 12</time_frame>
    <description>biological follow up and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of RIT</measure>
    <time_frame>Week 6 and Month 12</time_frame>
    <description>biological follow up and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunization analysis : detection of antibody anti epratuzumab</measure>
    <time_frame>Month 12</time_frame>
    <description>By ELISA assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90Y-DOTA-Epratuzumab blood pharmacokinetics</measure>
    <time_frame>Month 2</time_frame>
    <description>Detection of the radioactivity within the patient's blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of FLT3-ligand in plasma and correlation with efficacy and toxicity of RIT</measure>
    <time_frame>Month 12</time_frame>
    <description>by biological assay</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG</intervention_name>
    <description>2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)</description>
    <other_name>90Y-DOTA- hLL2 IgG and hLL2 IgG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic stem cell transplantation.</intervention_name>
    <description>At Day 0</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulines</intervention_name>
    <description>Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Acute lymphoblastic Leukemia (ALL) CD22 + B-type in RC1 with high risk&#xD;
&#xD;
          -  B-Cell Acute Lymphoblastic Leukemia (ALL) CD22+ beyond RC1.&#xD;
&#xD;
          -  Expression of CD22 ≥ 30% in tumor population evaluated by flow cytometry or&#xD;
             immunohistochemistry at diagnosis stage or relapse stage.&#xD;
&#xD;
          -  HLA-identical donor intra family or not, without major HLA mismatch (9 / 10th&#xD;
             accepted) without contra-indication for stem cell mobilization&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) ≤ 2&#xD;
&#xD;
          -  Having or not received previously Epratuzumab&#xD;
&#xD;
          -  Eligible for an allograft with reduced conditioning regimen&#xD;
&#xD;
          -  With a signed informed consent&#xD;
&#xD;
          -  Patient in age of children bearing with adequate contraception&#xD;
&#xD;
          -  Patient affiliated to or beneficiary of the National Health Service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T-cell ALL&#xD;
&#xD;
          -  Known hypersensibility to 90Y-DOTA-hLL2&#xD;
&#xD;
          -  Immunization against hLL2 for patients having already received one or several&#xD;
             injections of this antibody&#xD;
&#xD;
          -  Patient eligible for myeloablative conditioning regimen&#xD;
&#xD;
          -  Other prior malignancies must have had at least a 2-year disease-free interval with&#xD;
             the exception of successfully treated carcinoma skin cancer or carcinoma in situ of&#xD;
             the cervix.&#xD;
&#xD;
          -  Patient with progressive psychiatric condition.&#xD;
&#xD;
          -  HIV positive, hepatitis B-antigen positive, or hepatitis C positive patients who need&#xD;
             a treatment&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women with childbearing potential without effective contraception&#xD;
&#xD;
          -  Serious concomitant and uncontrolled infection&#xD;
&#xD;
          -  Usual contraindications in the allogeneic transplant:&#xD;
&#xD;
          -  Adult patient protected by the French law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD22 positive- lymphoblastic leukemia-RIT-Yttrium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Epratuzumab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

